Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

被引:62
作者
Eddahibi, S
Humbert, M
Fadel, E
Raffestin, B
Darmon, M
Capron, F
Simonneau, G
Dartevelle, P
Hamon, M
Adnot, S [1 ]
机构
[1] Fac Med Creteil, Dept Physiol, INSERM U492, F-94010 Creteil, France
[2] Hop Henri Mondor, AP HP, Dept Physiol, F-94010 Creteil, France
[3] Hop Antoine Beclere, AP HP, Serv Pneumol, UPRES EA2705, Clamart, France
[4] Hop Marie Lannelongue, UPRES EA2705, Serv Chirurg Thorac Vasc & Transplantat Cardiopul, F-92350 Le Plessis Robinson, France
[5] Univ Paris 05, Dept Physiol, Hop Ambroise Pare, Boulogne, France
[6] Univ Paris 06, INSERM U288, Paris, France
关键词
D O I
10.1172/JCI12805
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is a hallmark pathological feature of primary pulmonary hypertension (PPH). Here we found that PA-SMCs from patients with PPH grow faster than PA-SMCs from controls when stimulated by serotonin or serum and that these effects are due to increased expression of the serotonin transporter (5-HTT), which mediates internalization of indoleamine. In the presence of 5-HTT inhibitors, the growth stimulatory effects of serum and serotonin were markedly reduced and the difference between growth of PA-SMCs from patients and controls was no longer observed. As compared with controls, the expression of 5-HTT was increased in cultured PA-SMCs as well as in platelets and lungs from patients with PPH where it predominated in the media of thickened pulmonary arteries and in onion-bulb lesions. The L-allelic variant of the 5HTT gene promoter, which is associated with 5-HTT overexpression and increased PA-SMC growth, was present in homozygous form in 65% of patients but in only 27% of controls. We conclude that 5-HTT activity plays a key role in the pathogenesis of PA-SMC proliferation in PPH and that a 5HTT polymorphism confers susceptibility to PPH.
引用
收藏
页码:1141 / 1150
页数:10
相关论文
共 31 条
  • [1] Appetite-suppressant drugs and the risk of primary pulmonary hypertension
    Abenhaim, L
    Moride, Y
    Brenot, F
    Rich, S
    Benichou, J
    Kurz, X
    Higenbottam, T
    Oakley, C
    Wouters, E
    Aubier, M
    Simonneau, G
    Begaud, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) : 609 - 616
  • [2] SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION
    CHOMCZYNSKI, P
    SACCHI, N
    [J]. ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) : 156 - 159
  • [3] Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
    Deng, ZM
    Morse, JH
    Slager, SL
    Cuervo, N
    Moore, KJ
    Venetos, G
    Kalachikov, S
    Cayanis, E
    Fischer, SG
    Barst, RJ
    Hodge, SE
    Knowles, JA
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) : 737 - 744
  • [4] Eddahibi S, 1999, AM J RESP CRIT CARE, V159, pA165
  • [5] Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene
    Eddahibi, S
    Hanoun, N
    Lanfumey, L
    Lesch, KP
    Raffestin, B
    Hamon, M
    Adnot, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) : 1555 - 1562
  • [6] Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells - Relationship with the mitogenic action of serotonin
    Eddahibi, S
    Fabre, V
    Boni, C
    Martres, MP
    Raffestin, B
    Hamon, M
    Adnot, S
    [J]. CIRCULATION RESEARCH, 1999, 84 (03) : 329 - 336
  • [7] Eddahibi S, 2001, J PHARMACOL EXP THER, V297, P148
  • [8] EDDAHIBI S, 1997, AM J PHYSIOL, V275, pH1773
  • [9] Aminorex to fen/phen - An epidemic foretold
    Fishman, AP
    [J]. CIRCULATION, 1999, 99 (01) : 156 - 161
  • [10] Frid MG, 1997, CIRC RES, V81, P940